 To demonstrate that two doses of ProQuad administered by IM route are as immunogenic as two doses of ProQuad administered by SC route to healthy children 12 to 18 months of age in terms of antibody response rates to measles, mumps, rubella and to varicella at 42 days following the second dose of ProQuad 